药石科技: 南京药石科技股份有限公司向不特定对象发行可转换公司债券受托管理事务报告（2024年度）

Group 1 - The company, Nanjing Pharmablock Sciences Co., Ltd., issued convertible bonds to unspecified investors, with a total issuance of 11.5 million bonds at a face value of 100 RMB each, raising a total of 1.15 billion RMB [3][5][23] - The net proceeds from the bond issuance, after deducting various fees, amounted to approximately 1.14 billion RMB [3][23] - The bonds are set to mature in six years, with an annual interest rate that increases progressively from 0.3% in the first year to 2.0% in the sixth year [5][6] Group 2 - In 2024, the company reported a revenue of 1.688 billion RMB, a decrease of 2.12% year-on-year, while the net profit attributable to shareholders increased by 11.24% to 220 million RMB [21][22] - The company achieved a net cash flow from operating activities of 303 million RMB, reflecting a 22.68% increase compared to 2023 [21][22] - The company’s new orders in the CDMO segment grew by 12.43% year-on-year, with a 31.12% increase in order quantity [21][22] Group 3 - The initial conversion price for the bonds was set at 92.98 RMB per share, with subsequent adjustments based on stock performance and dividend distributions [8][29] - The bond's credit rating has been maintained at AA, with a stable outlook as per the annual tracking reports [18][26] - The company has implemented measures to manage customer credit and optimize cash flow, contributing to improved financial performance [21][22]